Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes

References

• Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–1330.
   PubMed Web of Science ®Google Scholar
• Qu H, Li J, Wu L, et al. Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease. Mol Med Rep. 2016;14:2423–2430.
   PubMed Web of Science ®Google Scholar
• Goldring MB, Otero M, Plumb DA, et al. Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis. Eur Cell Mater. 2011;21:202.
   PubMed Web of Science ®Google Scholar
• Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015;5:194–222.
   PubMed Web of Science ®Google Scholar
• Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biology. 2014;2:411–429.
   PubMed Web of Science ®Google Scholar
• Yu Z, Visse R, Inouye M, et al. Defining requirements for collagenase cleavage in collagen type III using a bacterial collagen system. J Biol Chem. 2012;287:22988–22997.
   PubMed Web of Science ®Google Scholar
• Manka SW, Carafoli F, Visse R, et al. Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Nat Acad Sci. 2012;109:12461–12466.
   PubMed Web of Science ®Google Scholar
• Antonicelli F, Bellon G, Debelle L, et al. Elastin-elastases and inflamm-aging. Curr Top Dev Biol. 2007;79:99–155.
   PubMed Web of Science ®Google Scholar
• Fields GB. Interstitial collagen catabolism. J Biol Chem. 2013;288:8785–8793.
   PubMed Web of Science ®Google Scholar
• Gudmann NS, Karsdal MA. Type II Collagen. In: Karsdal MA, editor. Biochemistry of Collagens, Laminins and Elastin. Amsterdam, Nederland: Elsevier; 2016. p. 13–20.
   Google Scholar
• Ismail HM, Yamamoto K, Vincent TL, et al. Interleukin-1 acts via the JNK-2 signaling pathway to induce aggrecan degradation by human chondrocytes. Arthritis & Rheumatol. 2015;67:1826–1836.
   PubMed Web of Science ®Google Scholar
• Ismail HM, Yamamoto K, Vincent T, et al. A significant role for the JNK pathway in regulating interleukin 1 induced-aggrecan degradation in human articular chondrocytes. Osteoarthritis and Cartilage. 2015;23:A152.
   Web of Science ®Google Scholar
• Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem. 2011;112:3507–3514.
   PubMed Web of Science ®Google Scholar
• Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthr Cartil. 2010;18:1441–1447.
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S254–S258.
   PubMed Web of Science ®Google Scholar
• Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2006;14:839–848.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• McClean PL, Hölscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer’s disease. Neuropharmacology 2014;86:241–258.
   PubMed Web of Science ®Google Scholar
• Vinué Á, Navarro J, Herrero-Cervera A, et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia 2017;60:1801–1812.
   PubMed Web of Science ®Google Scholar
• Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators of Inflam. 2016;2016:1.
   Web of Science ®Google Scholar
• Hansen MS, Tencerova M, Frølich J, et al. Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism. Basic Clin Pharmacol Toxicol. 2018;122:25–37.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Bougault C, Attali C, inventors, Assistance Publique Hopitaux de Paris, assignee. Treatment of osteoarthritis with incretin hormones or analogues thereof. U.S. Patent No. 9,592,272. 2017 March 14.
   Google Scholar
• FDA. Sanofi new drug application for lixisenatide accepted for review by FDA; 2013 Feb 19; Available from: Drugs.com/PRNewsire.
   Google Scholar
• Kim Y, Zheng X, Ansari Z, et al. Mitochondrial aging defects emerge in directly reprogrammed human neurons due to their metabolic profile. Cell Rep. 2018;23:2550–2558.
   PubMed Web of Science ®Google Scholar
• Smith MD, Triantafillou S, Parker A, et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24:365–371.
   PubMed Web of Science ®Google Scholar
• Fernandes JC, Martel‐Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237–246.
   PubMed Web of Science ®Google Scholar
• Makki MS, Haqqi TM. Histone deacetylase inhibitor vorinostat (SAHA) suppresses IL-1β-induced matrix metallopeptidase-13 expression by inhibiting IL-6 in osteoarthritis chondrocyte. Am J Pathol. 2016;186:2701–2708.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Serge H, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.
   PubMed Web of Science ®Google Scholar
• Lim H, Kim HP. Matrix metalloproteinase-13 expression in IL-1β-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways. Arch Pharm Res. 2011;34:109–117.
   PubMed Web of Science ®Google Scholar
• Mohetaer M, Li G, Wang Y, et al. Protective effects of gemigliptin against type II collagen degradation in human chondrocytes. Biomed Pharmacother. 2018;104:590–594.
   PubMed Web of Science ®Google Scholar
• Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin‐1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c‐jun N‐terminal kinase, and nuclear factor κB: differential regulation of collagenase 1 and collagenase 3. Arthritis & Rheumatol. 2000;43:801–811.
   PubMed Web of Science ®Google Scholar
• Zandi E, Rothwarf DM, Delhase M, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91:243–252.
   PubMed Web of Science ®Google Scholar